Bayer Consumer Health Journey Still Short Of Destination
This article was originally published in The Pink Sheet
Executive Summary
Bayer says issues encountered after acquiring Merck & Co.’s consumer brands two years ago have meant slower growth than expected. But it suggests that’s not a precedent for its planned mega-merger with Monsanto.
You may also be interested in...
Bayer Reiterates Pharma Commitment Post-Monsanto, Plays Up Pipeline
German conglomerate says five recent launches led by Xarelto and Eylea are expected to bring in more than $11bn in peak sales, a 33% increase over previous projections. CEO Baumann pledges to make the investments needed to continue growing the pharma business.
Bayer's ClariSpray Brings Hint Of Familiar Brand To Nasal Allergy Space
ClariSpray is the same formulation as GSK Consumer Healthcare's Flonase Allergy Relief, but Bayer is not making all of the same claims because OTC Flonase for another year has exclusivity among OTC intranasal corticosteroids for eye-related allergy relief.
Bayer Leveraging Consumer Growth From Product Launches, More Shelf Space
Global consumer chief Erica Mann says OTC drug and nutritional product sales should increase during the current quarter as consumers' self-care focus turns to sunscreens and allergy treatments. Bayer plans around 30 consumer product launches later in the year.